Infectious Diseases News
Get insights on infectious diseases with press releases highlighting research, treatments, and policies addressing global health challenges. Stay informed on key developments in combating infectious diseases and explore opportunities in public health initiatives.
Mar 17, 2026 at 4:00 PM
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2025. “Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2’s boron chemistry pipeline and...
Mar 17, 2026 at 8:00 AM
Real Time Medical Systems to Present Data-Driven Strategies for Reducing Readmissions at AAPACN 2026
BALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems (Real Time), the industry-leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its participation in the American Association for Post-Acute Care Nursing (AAPACN) 2026 Conference, taking place March 17–20 in Orlando, FL. As nursing professionals convene to explore best practices and emerging clinical innovations, Real Time and North Shore Health will highlight how live, data-driven approaches help post-acu...
Mar 17, 2026 at 6:50 AM
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the long-term effectiveness of the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and its 4-valent HPV vaccine, GARDASIL® (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases at the EUROGIN Interna...
Mar 16, 2026 at 4:15 PM
Veracyte Names Kevin Haas as Chief Development and Technology Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Names Kevin Haas as Chief Development and Technology Officer...
Mar 16, 2026 at 4:04 PM
As Health Care is Slashed Nationwide, AHF and FLUX Create a Health Care Center That is ‘Open for ALL’
LOS ANGELES--(BUSINESS WIRE)--As Health Care is Slashed Nationwide, AHF and FLUX Create L.A. Health Care Center ‘Open for ALL’...
Mar 16, 2026 at 9:00 AM
OpenEvidence and AAO-HNSF Pioneer a New Model for Updating Clinical Practice Guidelines
ALEXANDRIA, Va. & MIAMI--(BUSINESS WIRE)--AAO-HNSF and OpenEvidence use AI to update clinical practice guidelines and align standards of care with the latest clinical evidence as it evolves....
Mar 13, 2026 at 11:44 AM
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
PHILADELPHIA--(BUSINESS WIRE)--GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk...
Mar 12, 2026 at 6:16 PM
AIDS Groups Protest City-Planned Cuts to HIV/AIDS Care in Chicago
CHICAGO--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) and its Chicago area affiliate organizations the South Side Help Center (SSHC) and CALOR will team to host a street protest and give testimony before the Chicago Department of Health’s HIV Planning Committee at an emergency public meeting on Friday, March 13, to oppose and halt planned grant funding cuts. The organizations’ actions are part of an effort to restore funding of AHF's HIV Primary Care Services and SSHC's Early Intervention...
Mar 12, 2026 at 6:00 PM
Aptar Pharma and COVIRIX Medical Partner to Develop Inhalable Antiviral Treatments
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma and COVIRIX Medical collaborate to assess feasibility of adapting Aptar Pharma’s proprietary DPI platform for antiviral delivery....
Mar 12, 2026 at 5:30 PM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Media & Journalist Tools
From headlines to storylines—Business Wire delivers the news you need, when you need it.